Brett Fishbin Analyst PerformanceVP, Senior Equity Research Analyst at KeyCorpBrett Fishbin is a stock analyst at KeyCorp focused in the medical sector, covering 10 publicly traded companies. Over the past year, Brett Fishbin has issued 20 stock ratings, including buy and hold recommendations. While full access to Brett Fishbin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brett Fishbin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings28 Last 1 YearsBuy Recommendations88.89% 24 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution27RatingsDistribution of strong buy, buy, hold, and sell ratings by Brett Fishbin.RatingPercentageCount Strong Buy0.0%0 ratings Buy88.9%24 ratings Hold11.1%3 ratings Sell0.0%0 ratingsOut of 27 total stock ratings issued by Brett Fishbin at KeyCorp, the majority (88.9%) have been Buy recommendations, followed by 11.1% Hold.Best & Worst CallsBest Call000.0%TXNApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%INSPJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNYSE60.0% of companies on NYSE6 companiesNASDAQ40.0% of companies on NASDAQ4 companiesBrett Fishbin, an analyst at KeyCorp, currently covers 10 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.Coverage FocusSector IconSectorPercentageMedical8 companies80.0%Computer and Technology2 companies20.0%Brett Fishbin of KeyCorp specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.Coverage IndustriesIndustryPercentageMED INSTRUMENTS4 companies40.0%MED PRODUCTS2 companies20.0%MEDICAL SERVICES1 company10.0%MEDICAL INFO SYS1 company10.0%SEMI - GENERAL1 company10.0%COMP - SOFTWARE1 company10.0% About Brett FishbinBrett Fishbin is a Vice President and Equity Research Analyst for KeyBanc Capital Markets Inc. With the firm since 2017, he focuses his research on the Medical Technology sector. Before his promotion to senior analyst, he was a Research Associate on KBCM’s healthcare team for six years, including five in MedTech. Brett's previous investment experience includes actively managing a portion of the University of Wisconsin’s endowment fund as part of the Applied Securities Program, as well as an internship at Heartland Advisors in Milwaukee. Fishbin earned a Bachelor of Business Administration in finance and an master's degree in Applied Securities Analysis from the University of Wisconsin-Madison. He also holds the Series 7, 63, 86, and 87 industry certifications. Follow on LinkedIn Brett Fishbin's Ratings History at KeyCorp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSOLVSolventum4/27/2026Lower Price Target$68.55$92.00Overweight$0.0000.00% ROIRMDResMed4/27/2026Lower Price Target$219.86$290.00Overweight$0.0000.00% ROIICUIICU Medical4/27/2026Lower Price Target$124.82$164.00Overweight$0.0000.00% ROISOLVSolventum2/27/2026Boost Price Target$77.25$99.00Overweight$0.0000.00% ROIICUIICU Medical2/20/2026Boost Price Target$149.74$180.00Overweight$0.0000.00% ROIRMDResMed1/30/2026Reiterated Rating$257.83$302.00Overweight$0.0000.00% ROISOLVSolventum1/26/2026Upgrade$78.91$97.00Overweight$0.0000.00% ROILIVNLivaNova12/19/2025Initiated Coverage$62.08$81.00Overweight$0.0000.00% ROILIVNLivaNova12/18/2025Initiated Coverage$62.82$81.00Overweight$0.0000.00% ROIICUIICU Medical11/7/2025Boost Price Target$139.71$175.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. INSPInspire Medical Systems11/4/2025Reiterated Rating$73.76Sector Weight$0.0000.00% ROIRMDResMed10/31/2025Boost Price Target$252.14$299.00Overweight$0.0000.00% ROIITGRInteger10/21/2025Lower Price Target$107.38$133.00Overweight$0.0000.00% ROIICUIICU Medical10/21/2025Lower Price Target$117.34$173.00Overweight$0.0000.00% ROIALCAlcon10/21/2025Lower Price Target$75.46$91.00Overweight$0.0000.00% ROIINSPInspire Medical Systems8/5/2025Downgrade$130.79Sector Weight$0.0000.00% ROIRMDResMed8/1/2025Boost Price Target$272.16$298.00Overweight$0.0000.00% ROISTESTERIS7/22/2025Boost Price Target$223.65$288.00Overweight$0.0000.00% ROIINSPInspire Medical Systems7/22/2025Lower Price Target$128.10$197.00Overweight$0.0000.00% ROISOLVSolventum6/6/2025Initiated Coverage$75.28Sector Weight$0.0000.00% ROIRMDResMed4/24/2025Set Price Target$232.12$274.00$000.0000.00% ROITXNTexas Instruments4/24/2025Lower Price Target$160.82$215.00Overweight$000.0000.00% ROIALCAlcon3/31/2025Boost Price Target$94.59$112.00Overweight$00.0000.00% ROIRMDResMed1/31/2025Boost Price Target$242.87$280.00Overweight$000.0000.00% ROISLPSimulations Plus1/24/2025Boost Price Target$33.96$37.00Overweight$00.0000.00% ROIITGRInteger1/24/2025Boost Price Target$143.32$154.00Overweight$00.0000.00% ROIINSPInspire Medical Systems1/24/2025Reiterated Rating$185.53$234.00Overweight$00.0000.00% ROIALCAlcon1/24/2025Lower Price Target$89.24$105.00Overweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
